Assessing Spare Parts Availability Before Buying Used Equipment

The most expensive used equipment purchase is the one that works perfectly on delivery and cannot be maintained two years later. Parts availability is not a maintenance consideration that belongs to the biomedical department after purchase; it is a valuation input that determines what the device is worth and how long it will remain useful. A device with an unavailable wear part, an unsupported control module or a discontinued consumable has a defined life irrespective of its condition. This guide sets out what a parts availability assessment has to produce, who owns each step, and where it usually breaks.

What This Process Has to Produce

The output is a written position on whether the device can be maintained over the period the buyer intends to use it, together with the specific items that determine the answer. That means three results: an inventory of the parts that matter, evidence about the availability of each, and a decision about the device that follows from it.

The assessment is not a general enquiry about whether spare parts exist. It is an enquiry about which parts are likely to be needed, which of those are single-sourced, long-lead or already discontinued, and what the consequence is if any of them cannot be obtained. The extractable summary is this: a parts availability assessment identifies the wear and failure-prone parts for the specific device, evidences the supply position for each, and converts that evidence into a maintenance and valuation decision.

Who Owns Each Step

Availability assessment fails when it is delegated entirely to the seller or entirely to procurement, because neither party holds the technical knowledge needed to know which parts matter. The seller holds information about the specific unit and often about the supply chain it uses. Procurement holds commercial routes to suppliers. Neither knows which component’s failure would remove the device from service.

The technical owner is the person who understands the device’s function and its failure modes, which in a buyer’s organisation is the biomedical or technical function. That function should define the parts inventory and the criticality classification. Procurement should obtain availability evidence against that list rather than against a general enquiry. The seller should provide the parts list and any service history, and where the seller asserts availability, the assertion should be recorded with its basis rather than accepted as a statement. Where the device’s continued use depends on consumables or single-use items, the buyer is responsible for confirming legality, labelling and any applicable reprocessing position in their own market, and availability of a consumable does not resolve that question.

The Sequence and Its Dependencies

The sequence runs from the device to the decision, and each step narrows the enquiry. Skipping a step produces an assessment that is broad and therefore unhelpful.

1. Establish what the device is, including model, configuration and production era, because availability differs within a model family. 2. Obtain the parts list and the service documentation, which together identify the components that exist and how they are supplied. 3. Identify wear parts and failure-prone components, drawing on the service history where one exists and on the manufacturer’s maintenance guidance. 4. Classify by criticality: which components stop the device, which degrade performance, and which are cosmetic. 5. Check the supply position for each critical item: current supply, lead time, single-source risk, and secondary market depth. 6. Check the consumable and accessory position, including whether the sets and sensors the device requires are still supplied. 7. Check the software and firmware position, because an unsupported version can affect the device as much as an unavailable part. 8. Record the conclusion, including what was not established and what would change the decision.

The dependency that carries the most weight is the fourth step. Without a criticality classification, an availability enquiry produces a list of parts that can be bought, which is not the question. The question is whether the parts that cannot be bought are the ones that matter.

A second dependency is the age of the information. Availability is not a fixed property; it changes as a product moves through its lifecycle and as the secondary market fills and empties. An assessment made in one month can be wrong in the next, which is why the check should be repeated at points where the answer matters, such as before a large purchase or before a service contract is renewed. Repeating a structured check is quick; reconstructing one is not.

Documents Generated Along the Way

The assessment produces a small document set, and each item has a specific reader. The parts inventory is read by the technical function; the availability evidence is read by procurement; the decision rationale is read by whoever reviews the purchase later.

The date on each availability confirmation matters more than it appears. Supply positions change quickly, particularly for equipment approaching the end of its supported life, and a confirmation obtained during a purchase negotiation may be invalid six months later when the first repair is needed. Recording the date allows the assessment to be refreshed on a schedule rather than on an instinct, and it tells a later reader how much confidence the original conclusion deserves.

Where the Process Usually Breaks

Six failures account for most availability assessments that turn out to be wrong, and each of them is avoidable with a modest amount of discipline.

• The assessment is made at model level rather than at configuration level, so the parts identified do not all apply to the unit being purchased.
• Wear parts are omitted because the focus falls on the electronics, and wear parts are precisely the components that are needed first.
• Availability is confirmed for a part without asking about lead time, so a two-month wait is discovered when the device is already out of service.
• Consumables are treated as a purchasing matter rather than a technical one, and the device is purchased against items that are no longer supplied in the required form.
• The software position is not assessed, so a device that requires a specific version to function is acquired without knowing whether that version can be obtained or supported.
• The seller’s assertion of availability is recorded as a fact rather than as a claim, which leaves the buyer unable to show what was known at the time of purchase.

Handling Exceptions and Partial Failures

Exceptions are normal, and the useful response is to quantify rather than to judge. Where a critical part is available only from the secondary market, the assessment should record how deep that market appears to be, because a single source can disappear as readily as a manufacturer’s supply.

Where a component is available only as part of a larger assembly, the practical cost of a repair changes, and that should be reflected in the assessment rather than treated as a detail. Where a part is unavailable and cannot be substituted safely, the device has a defined operating life, and the honest position is to state it and price it rather than to acquire the equipment as though the problem will resolve. Where the device depends on a consumable that is single-use, the buyer must confirm legality, labelling and any applicable reprocessing position in their own market, and an available consumable that cannot lawfully be used is not availability at all.

What to Record for Audit and Resale

The availability assessment has a second life at resale, because a buyer of the same device will ask the same questions. A seller who holds the assessment can answer them with evidence, and a buyer who inherited one can update it rather than repeat it.

Keep the parts inventory, the criticality classification, the availability evidence, the consumable position and the decision rationale with the equipment file. Record the dates on which availability was checked, because the position changes and a two-year-old check describes a different market. Where a part was substituted, record the specification used, because that decision affects how the device is characterised later. Our guide to how hospitals secure critical spare parts before budget resets covers the procurement side of the same problem, and the wider context sits in the knowledge hub, with equipment descriptions on the marketplace store and maintenance material in the industry hub. The servicing framework these decisions sit within is covered by AAMI’s medical device servicing material, independent guidance from organisations such as ECRI is a useful reference on maintenance risk, and cross-market expectations for devices and their support are summarised by the WHO medical devices programme.

Because the assessment is essentially a risk statement, it is worth expressing it in terms a finance or clinical audience can act on. The useful output is not a list of parts but a sentence such as: this device can be maintained for the intended period provided these two components remain available, and if either becomes unavailable the device’s role ends when the last item is consumed. That formulation makes the exposure visible, supports a price negotiation, and gives the technical function a defined item to monitor rather than a general concern to remember. National workplace material such as the HSE health services guidance is a reminder that the duty to keep equipment safe and available continues throughout that period, and the device-side obligations that apply irrespective of the maintenance arrangement are illustrated by the MHRA guidance on regulating medical devices.

Part of the Buying Pre-Owned Medical Equipment guide.